Direct answer. Microvillus inclusion disease (MVID), also called microvillous inclusion disease or Davidson disease, is a rare congenital enteropathy that can cause severe watery diarrhoea and impaired absorption from infancy. Dated genetic definition It needs specialist assessment and nutritional support. Confidence is high in the disease distinction; current individual prognosis, drug benefits and transplant selection are not established by this bounded review.
- Severe infant diarrhoea needs assessment without waiting for a chronic-duration label.
- A congenital intestinal-cell disorder is different from an ordinary infection or loss of bowel length.
- Pathology and genetic results should be interpreted together by the specialist team.
- Nutrition, line safety and other-organ findings require continuing care; fewer stools alone does not settle every outcome.
Table of contents
- Evidence summary
- What microvillus inclusion disease is
- MYO5B, microvilli and intestinal absorption
- Early symptoms and the diagnostic differential
- Biopsy, genetic results and related variants
- Parenteral nutrition and the individual feeding plan
- Catheter safety and home-care training
- Growth, liver findings and other monitoring
- Transplant discussions and the limits of treatment claims
- Urgent dehydration, illness and emergency help
- Inheritance, supplements and human-evidence boundaries
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| MVID recognition and genetics | Dated NLM education plus selected academic review | Public institutional routes; complete contributor/source-study receipts unclosed. | Specific diagnosis, not a home symptom or gene-variant rule. |
| Nutrition and line safety | Paediatric PN and general home-PN education | Separate provider finance; no device or nutrient-product efficacy clearance. | Training and individual monitoring; adult catheter instructions not transferred. |
| Transplant or drug benefit | Selected dated context; no cleared comparative outcome | Complete intervention funder/author chain not established. | No independent ranking, personal eligibility or prognosis estimate. |
What microvillus inclusion disease is
MedlinePlus describes early watery diarrhoea, dehydration, malnutrition and impaired growth. A less severe variant can have different nutritional needs. Selected dated presentation.
The names microvillus inclusion disease, microvillous inclusion disease and Davidson disease refer to the same condition family here. “Intractable diarrhoea of infancy” is a broader historical description and does not, by itself, identify MVID. Ask whether the diagnosis is confirmed or suspected and what finding establishes it. Keep the exact pathology and genetic reports with the clinical summary. This guide does not diagnose the condition from stool appearance, family history or a single episode of poor feeding. A short-bowel diagnosis, infection and congenital enteropathy are different explanations that need their own evidence.
MYO5B, microvilli and intestinal absorption
MYO5B helps organize cell polarity and membrane recycling. Disrupted function can impair the intestinal cells’ microvilli and absorption of nutrients and fluid. Dated MYO5B mechanism.
Microvilli are cellular structures, not a segment of bowel that can be measured from an external photograph. Ask the team to explain the difference between abnormal intestinal-cell function and a reduction in bowel length after surgery. A molecular explanation does not identify which treatment will benefit an individual, and it does not demonstrate that a marketed product rebuilds the brush border. Mechanism claims should be separated from demonstrated human outcomes. If a report uses gene, protein or tissue terms that appear inconsistent, request an explanation rather than deciding that one label rules out another.
Early symptoms and the diagnostic differential
The 2018 clinical review describes specialist evaluation of severe infant diarrhoea using clinical history, stool findings, biopsy assessment and genetic testing. Dated diagnostic framework.
Tell clinicians when symptoms first started, how the pattern changed and what feeding or treatment was in place at each stage. Do not wait weeks to meet a definition of “chronic” before reporting severe newborn symptoms. Record what has been tested and what remains under consideration, including whether an acquired cause has been assessed. Diarrhoea, vomiting and impaired growth do not distinguish every congenital disorder by themselves. Ask who is coordinating the evaluation and which result would change the working diagnosis. This guide supplies no fasting trial, stool-volume cutoff, formula challenge or rule for deciding a diagnosis at home.
Biopsy, genetic results and related variants
The review discusses intestinal histology, selected staining and electron microscopy for microvillus inclusions; it also recognizes STX3-associated variant disease. Selected pathology and variant context.
Ask which tissue finding was present, which method assessed it and how the genetic result fits that finding. A report of a variant of uncertain significance needs the genetics team’s interpretation; it should not be silently treated as a confirmed pathogenic result. If an immune or another-organ abnormality is found, ask whether it changes the diagnosis or requires a separate assessment. Do not assume that every related gene produces an identical intestinal or wider-health condition. These questions are not a recommendation that every infant undergo every possible test. The responsible team must explain the actual procedure, its risks, the purpose of the sample and the next step if the result is inconclusive.
Parenteral nutrition and the individual feeding plan
The dated MVID description recognizes prolonged intravenous nutritional support in classic disease, with variability in milder presentations. CUH explains that parenteral nutrition delivers nutrients through a venous catheter when eating or tube feeding is inadequate. Dated support context; Child nutrition explanation.
Ask how nutrition and hydration are being provided now and what the team is monitoring before any change. Food intolerance, fluid loss and nutritional adequacy need separate explanations. Do not stop milk, replace a formula, increase fluids, adjust a pump or reduce intravenous support from an online schedule. A home feeding challenge can be dangerous in an infant with severe losses. Ask who reviews oral or tube intake and what written advice applies if a feed or infusion cannot be given. This article provides no recipe, bag composition, fluid amount or personal weaning instruction.
Catheter safety and home-care training
CUH’s general home-PN source identifies potentially serious line infection, blockage and thrombosis, and emphasizes specialist supervision. Its adult equipment procedures are not instructions for an infant. Selected general line-risk context.
Request practical training for the child’s actual catheter, pump and supplies. The written plan should identify a contact for fever or other illness, a damaged or displaced line, leakage and equipment failure. Obtain the team’s emergency instructions rather than improvising a flush, disconnecting equipment or using a catheter for another purpose. Ask who orders replacement supplies and how an interruption will be managed. A general education leaflet cannot establish competence with a particular device. For nursery, school or travel, ask the clinical team what information and training caregivers need and which tasks must remain with trained staff.
Growth, liver findings and other monitoring
CUH’s paediatric nutrition leaflet describes assessment of electrolytes, kidney and liver function and growth. The 2018 review also notes MYO5B-related cholestasis that is not simply explained by PN exposure. Selected monitoring roles; Selected liver distinction.
Ask which findings relate to the underlying disorder, which may relate to nutritional support and which remain uncertain. A liver result should not automatically be assigned to the catheter or nutrient bag without assessment. Request the purpose of each follow-up investigation and how results will reach the responsible team. Keep growth records, relevant laboratory results and changes in the care plan together. This review sets no universal laboratory schedule or transplant threshold. An improvement in stool frequency is not, by itself, a complete account of nutrition, hydration, growth or other-organ health.
Transplant discussions and the limits of treatment claims
The dated review describes intestinal or liver–intestinal transplantation as a specialist consideration in selected MVID complications. It does not establish individual eligibility or an independently verified outcome comparison. Bounded dated transplant context.
If transplantation is discussed, ask what clinical problem it would address, which organs are being considered, the alternatives and the uncertainties. Request the current transplant service’s assessment and financial disclosures for the evidence it uses. A diagnosis alone is not a transplant recommendation or a guarantee of nutritional independence. Drug-development announcements and a registered study also require careful distinction from an established indication and a proven patient benefit. No current drug ranking, trial-enrolment rule or cure claim is supplied here. This guide does not turn a research mechanism into a personal treatment option.
Urgent dehydration, illness and emergency help
Unusual drowsiness, reduced urine or fewer wet nappies can require urgent dehydration assessment. Breathing difficulty, blue or grey colour, collapse or difficulty waking a child requires emergency help. NHS dehydration signs; NHS emergency signs.
Use the local emergency route; UK guidance uses 999 for an emergency. Tell clinicians about the congenital enteropathy, current nutritional route, catheter and recent changes. Do not wait for every warning sign or for a routine appointment when the infant is seriously unwell. Use the child’s clinical emergency plan for fever or suspected line problems, and seek urgent advice if that plan is unavailable or unclear. No home fluid recipe, electrolyte dose, catheter intervention or emergency feeding regimen is prescribed here.
Inheritance, supplements and human-evidence boundaries
The MedlinePlus description identifies autosomal recessive inheritance. Family testing and recurrence counselling need the actual diagnosis and genetic findings. Dated inheritance context.
Ask which relatives may need counselling, what a test can establish and how an uncertain finding will be handled. This article gives no individual recurrence percentage or reproductive-testing recommendation. Share every prescription, nutritional product and supplement with the team. NCCIH’s dated precautions support disclosing nonprescription ingredients before procedures or treatment changes. Generic supplement precautions.
No independently cleared supplement benefit for correcting MVID is established here. Prescribed nutrition is different from a marketed brush-border cure. Animal, cell and organoid findings are excluded from patient-benefit conclusions. Human comparative evidence needs the original clinical population, intervention, comparator, follow-up, harms and full funding/conflict chain; public archive hosting does not supply that clearance.
Funding and source roles
Research funding at a glance
16 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
NLM genetics education is dated July 2014 and does not provide a current detailed care algorithm. The 2018 academic review is a bounded diagnostic and mechanism source; its declared absence of conflicts and indexed public grants do not close all outside or supporting-study receipts. Current CUH accounts are separate from national NHS policy. Source-specific financial gaps prevent an independent comparative-treatment verdict.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NLM microvillus inclusion disease, July 2014 | Separate budget, dated gift authority and editorial process. Page/reviewer and cited-study finances unclosed. | United States; NLM/NIH/HHS, Bethesda, Maryland. | Tier 2 public genetics context, provisional. | C provisional — scientific review favors accuracy; dated education and unresolved contributor/study interests limit use. |
| NLM MYO5B gene, July 2014 | Separate budget, dated gift authority and editorial process. Page/reviewer and cited-study finances unclosed. | United States; NLM/NIH/HHS, Bethesda, Maryland. | Tier 2 public genetics context, provisional. | C provisional — scientific review favors accuracy; dated education and unresolved contributor/study interests limit use. |
| Thiagarajah and colleagues infant-diarrhea review, June 2018 | Declares no conflicts; PDF project funding unstated. Separate grant metadata identifies NIDDK support; outside/employer and study receipts unclosed. | Authors United States and Canada; PediCODE-hosted original. | Tier 2 academic clinical context, provisional. | C provisional — actual clinical/declaration text read; dated expert synthesis and financial gaps remain. |
| PubMed infant-diarrhea review record, 2018 | Indexed NIDDK/NIH/HHS grants include R01 DK048370 and consortium grants; not a complete ledger or page-specific allocation. | Authors United States/Canada; NLM index United States, Bethesda. | Tier 3 financial/bibliographic metadata. | B provisional — actual record and grant list read; indexing aids tracing but does not verify complete outside receipts. |
| CUH child parenteral nutrition, September 2024 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; Cambridge University Hospitals, Cambridge, England. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| CUH home parenteral nutrition, May 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; Cambridge University Hospitals, Cambridge, England. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS serious childhood illness, August 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; national NHS website, distinct from trusts. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS dehydration, May 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; national NHS website, distinct from trusts. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS national content policy, October 2022 | DHSC funding and no advertising/corporate sponsorship stated in its own policy. Full current contributor, source-study and page receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B provisional — disclosed safeguards and accountability; review due October 2025 passed. This policy does not identify provider-trust receipts. |
| CUH audited annual accounts, 2025–26 | NHS commissioners, private/overseas care, research/training, gifts, rent/services; NIHR infrastructure and industry/charity partnerships separately described. Page/reviewer allocations unclosed. | United Kingdom; Hills Road, Cambridge, England. | Tier 3 institutional financial report. | B provisional — statutory audited reporting favors accuracy; provider/budget interests remain. Notes 2.1–2.3 and partnership discussion read; no source-trial clearance. |
| NCCIH supplement precautions, January 2019 | Separate appropriations history and gift authority. Page/contributor and cited-study receipts unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 2 public safety context, provisional. | C provisional — scientific accountability favors accuracy; dated summary and unclosed trial finances do not establish condition-specific benefit. |
| NCCIH appropriations history through FY2024 | Historical congressional appropriations table. No current-year enacted amount, accepted donor ledger or condition-page allocation inferred. | United States; NIH/HHS federal budget jurisdiction. | Tier 3 institutional fiscal reporting. | B provisional — transparent dated table favors accuracy; budget/mission incentives and missing page/trial allocations remain. |
| NCCIH Gift Fund authority and contact | Permitted gifts to public research agency; authority is not proof of a named accepted donor or sponsored page. Full receipt allocation unclosed. | United States; 31 Center Drive, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B provisional — explicit process/contact supports accuracy; fundraising/mission interests and donor gaps remain. |
| NLM budget justification, FY2027 | Congressional budget authority; FY2026 enacted and FY2027 requested columns are distinct. Whole-library support, not page receipts. | United States; NLM/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional fiscal original. | B provisional — actual 20-page table/programme text read; public accountability helps, budget interests and page allocations remain. |
| HHS gift-authority memorandum, August 2002 | Dated legal authority identifies NLM gift acceptance and outside co-sponsorship; no named current gift or page allocation inferred. | United States; federal HHS/NIH authority. | Tier 3 historical financial-authority original. | B provisional — actual four-page original read; age, implementation and complete donor receipts remain gaps. |
| NLM genetics editorial process, October 2023 | Institutional writing/selection process; separate appropriations and historical gift authority above. Individual interests unclosed. | United States; 8600 Rockville Pike, Bethesda, Maryland. | Tier 3 process and identity self-report. | B provisional — actual body/date read; review supports accuracy but does not clear finances or provide detailed care algorithms. |
Frequently asked questions
Is MVID the same as short-bowel syndrome? Ask whether the diagnosed problem is intestinal-cell function, bowel length or both. The labels are not interchangeable.
Does every patient need the same nutrition? The specialist team should explain the actual support requirement and why a proposed change is safe for that child.
Does a gene result replace pathology interpretation? Request the genetics and pathology teams’ explanation of how the findings support the confirmed diagnosis.
Can probiotics or vitamins repair the microvilli? No independently cleared human benefit for that purpose is established in this review. Discuss any proposed product with the care team.
Does transplantation automatically cure every aspect? Obtain the transplant team’s current explanation of the problem addressed, expected monitoring and remaining uncertainties.
Sources and funding notes
Actual NLM condition/gene bodies: 1 July 2014. Actual 2018 clinical/declaration passages read; separate PubMed grant metadata. CUH child PN approved 13 September 2024; home PN 12 May 2026. Numerical disease counts, universal nutritional outcomes, fasting/challenge instructions and adult catheter procedures excluded. Current trial-record retrieval was incomplete, so no trial status, drug efficacy or eligibility conclusion is adopted. Actual separate fiscal, gift and process originals do not clear clinical-page or source-study finances.
- NLM microvillus inclusion disease, July 2014 — Selected presentation, recessive inheritance and variable support needs.
- NLM MYO5B gene, July 2014 — Selected cell-polarity/absorption mechanism only.
- Thiagarajah and colleagues infant-diarrhea review, June 2018 — Selected pathology, variant, liver and transplant context; no outcomes.
- PubMed infant-diarrhea review record, 2018 — Grant/date/affiliation trace only; clinical content in separate original.
- CUH child parenteral nutrition, September 2024 — Selected intravenous-nutrition and monitoring roles; personal schedules excluded.
- CUH home parenteral nutrition, May 2026 — Selected general line-risk principles; adult equipment instructions not transferred to infants.
- NHS serious childhood illness, August 2026 — Emergency warning signs.
- NHS dehydration, May 2026 — Selected urgent dehydration signs; no fluid prescription.
- NHS national content policy, October 2022 — Dated national website provenance only.
- CUH audited annual accounts, 2025–26 — Actual 197-page original, selected financial notes and partnerships.
- NCCIH supplement precautions, January 2019 — Generic interaction/product disclosure only.
- NCCIH appropriations history through FY2024 — Historical fiscal route only.
- NCCIH Gift Fund authority and contact — Gift authority and headquarters only.
- NLM budget justification, FY2027 — Enacted/request distinction only.
- HHS gift-authority memorandum, August 2002 — Historical permission only.
- NLM genetics editorial process, October 2023 — Education scope and headquarters only.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.